Oncotelic Therapeutics Inc · OTC:OTLC
Oncotelic Therapeutics — 22nd Drug Discovery Strategic Summit (October 2026)
16 slides from Oncotelic Therapeutics's conference presentation, Oct 26, 2026
Slide 1: From Scientific Evidence to Drug Discovery: The Road to 100 Billion Vectors
22ND DRUG DISCOVERY STRATEGIC SUMMIT . « From Scientific Evidence to Drug Discovery: r b The Road to 100 Billion Vectols What could you discover = on an ordinary Tuesday afternoon? = * Saran Saund Chief Business Officer, Oncotelic Therapeutics October 22, 2026 Westin San Francisco Airport, Millbrae
Slide 2: How our PLA architecture gives each disease an equal vote
How our PLA architecture gives each disease an equal vote MONOLITHIC QUERY One monolithic synthesis PARTITIONED LITERATURE AGGREGATION (PLA) Breast Mantle-cell cancer lymphoma dain. 24 disease assessments — aggregate Partition the question. Investigate separately. Bring the evidence together. PLA pa
Slide 3: How AI followed a clue
How AI followed a clue Anthropic’s 200,000-cluster enzyme search and agent swarm 1.94 BILLION protein clusters searched 200,000 950* RT clusters (rounded) agent sessions Result: ART, a newly recognized system around a known RT Lab follow-up detected short RNAs. Biological function remains under stud
Slide 4: Anthropic: partition the search
Anthropic: partition the search Ue 200,000 RT clusters @ @ protein clusters 9 RT classes Retrons Group Il introns DGR ee ee ee ascociaea || Smurttin || tisedon ee ee ee Ueno Se Unplaced Novel | | ee ee Be PLA parallel: partition — investigate — aggregate Conceptual parallel; Anthropic does not call
Slide 5: Anthropic: deploy the swarm across partitions
Anthropic: deploy the swarm across partitions 950* 21.5 h 58 agent sessions elapsed search time max concurrent sessions Illustrative task lanes Family A a “ & +8 +9 <C=5 y ‘> F Analyze Review é Family B F.60 9-2) & (om (om, « p Analyze Review Family C cn i #-2-8< 5 1 Analyze Review 119 tasks, includ
Slide 6: Anthropic's result: ART
Anthropic’s result: ART Array-associated reverse transcriptases FO Le Le A TL Found mainly in viruses that Produces distinct short RNAs infect Bacteria Known enzyme, newly recognized RNA-producing system Lab follow-up detected short RNAs. Biological function remains under study. Source: Yoon etal, A
Slide 7: Our enterprise push: 100B vectors
Our enterprise push: 100B vectors a ff . PLANNED SCALE 100B protein vectors 500M proteins x ~200 representations each Proteins and their amino-acid positions Biological connections worth testing , PDAOAI planning scenario. Scale and performance remain to be demonstrated. Conceptual illustration. 07
Slide 8: Potential benefit: new antibiotics
Potential benefit: new antibiotics First planned application of our 100B protein-vector program Exploring new treatments for antibiotic-resistant infections Test activity Select a target Develop a compound and safety Use PLA to surface Identify and improve Test resistant bacteria, bacterial targets
Slide 9: PLA: discover what you don't know to search for
PLA: discover what you don’t know to search for One standard question. Every abstract. Traceable evidence. PLA - One abstract at a time _E ee Provide the gene names Aggregate 5 —» | involved in mTOR signaling —> Standardize names > 4,81 2 = that are reported in Consolidate this abstract. i human gen
Slide 10: PLA keeps rare clues in view
PLA keeps rare clues in view Every gene retains its paper references 4,812 115,130 2,369 2,443 human genes gene-paper links genes in 22 papers genes in just 1 paper Frequently reported genes Rare findings also survive Gene Distinct PMIDs Gene Distinct PMIDs MTOR 32,354 ZNF184 q AKT1 5,551 ZNF32 1 PI
Slide 11: Our patent timeline starts in 2023
Our patent timeline starts in 2023 Structures and methods for autonomous agents 2023 2024 November 29 November 29 Priority filing International PCT filing Mexico: patent granted* Additional applications progressing internationally PCT/US2024/057972 |WO2025117898A1 *Company-reported Mexico grant. Rig
Slide 12: How PLA enabled our HCC four-gene signature
How PLA enabled our HCC four-gene signature EVOLVE-1: 546 PATIENTS, NO OVERALL SURVIVAL BENEFIT Everolimus vs placebo: 7.6 vs 7.3 months median survival PLA separates Compare Focus on PLA builds the by cancer clinical results HCC failure candidate list iss - GR - Q& - Each cancer gets Kidney: benefi
Slide 13: HCC: three key results
HCC: three key results Discovery cohort: 364 patients EVOLVE-1 failed Everolimus: no overall survival benefit HR = 2.59 (1.8 - 3.74) 546 patients. HR 1.05 (95% Cl 0.86—-1.27) logrank P = 1.1e-07 Our HCC work HR 2.59 95% Cl 1.80-3.74. High versus low score. Expression Median survival: 84.4 vs 37.8 mo
Slide 14: Now the question is treatment benefit
Now the question is treatment benefit OBSERVED PROPOSED TESTS OF TREATMENT BENEFIT Survival association 1 Fix the four-gene test . Same genes, measurement method The four-gene signal reproduced and scoring formula before validation. in a separate patient cohort. 2. Test drug response in the lab Comp
Slide 15: More questions for the same engine
More questions for the same engine Nuclear YAP1-TEAD FOXO3 Taxane resistance Aging and cellular maintenance Potential upstream control point Modeling nuclear FOXO3 activity Candidate mechanisms that need the next experiment PDAOAI literature analyses. Candidate mechanisms require experimental valida
Slide 16: What is your next discovery question?
PDAOAI / ONCOTELIC-SAPU BIO REBOOT What is your next discovery question? Help test the biology and build the 100B-vector plan. SEAN Led Fastbot: researcher access to focused investigations. SELECTED PROJECTS MAY QUALIFY FOR Startup funding Oncotelic-SAPU development support Computational chemistry,
Oncotelic Therapeutics — 22nd Drug Discovery Strategic Summit (October 2026) on 6ix